New drugs for asthma

Nature Reviews Drug Discovery

Volumn 3, Issue 10, 2004, Pages 831-844

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMINOPHYLLINE; ANTIASTHMATIC AGENT; ATRIAL NATRIURETIC FACTOR; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE; FORMOTEROL; FUROSEMIDE; INTERLEUKIN 5; IPRATROPIUM BROMIDE; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TIPREDANE; UNINDEXED DRUG; URODILATIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNOPATHOGENESIS; MEDICAL RESEARCH; MOUSE; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SLOW DRUG RELEASE; SYSTEMIC DISEASE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CYTOKINES; GENE THERAPY; HUMANS;

EID: 6444222929     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1524     Document Type: Review

References (172)

1. Weiss, K. B. & Sullivan, S. D. The health economics of asthma and rhinitis. I. Assessing the economic impact. J. Allergy Clin. Immunol. 107, 3-8 (2001).
2. Tattersfield, A. E., Knox, A. J., Britton, J. R. & Hall, I. P. Asthma. Lancet 360, 1313-1322 (2002).
3. Barnes, P. J. Pathophysiology of asthma. Eur. Respir. Mon. 8, 84-113 (2003).
4. Payne, D. N. et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am. J. Respir. Crit. Care Med. 167, 78-82 (2003).
5. Barnes, P. J., Pedersen, S. & Busse, W. W. Efficacy and safety of inhaled corticosteroids: an update. Am. J. Respir. Crit. Care Med. 157, S1-S53 (1998).
6. Lipworth, B. J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch. Intern. Med. 159, 941-955 (1999).
7. Brattsand, R. & Axelsson, B. New Drugs for Asthma Vol. 2 (ed. Barnes, P. J.) 192-207 (IBC Technical Services Ltd, London, 1992).
8. Reynolds, N. A. & Scott, L. J. Ciclesonide. Drugs 64 511-519 (2004).
9. Taylor, D. A. et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. 160, 237-243 (1999).
10. Barnes, P. J. & Adcock, I. M. How do corticosteroids work in asthma? Ann. Intern. Med. 139, 359-370 (2003).
11. Schacke, H. et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101, 227-232 (2004).
12. Heck, S. et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13, 4087-4095 (1994).
13. Adcock, I. M., Nasuhara, Y., Stevens, D. A. & Barnes, P. J. Ligand-induced differentiation of glucocorticoid receptor trans-repression and transactivation: preferential targetting of NF-κB and lack of I-κB involvement. Br. J. Pharmacol. 127, 1003-1011 (1999).
14. Vayssiere, B. M. et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11, 1245-1255 (1997).
15. Belvisi, M. G. et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. 166, 1975-1982 (2001).
16. Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93-105 (2002).
17. Barnes, P. J. & Dixon, C. M. S. The effect of inhaled vasoactive intestinal peptide on bronchial hyperreactivity in man. Am. Rev. Respir. Dis. 130, 162-166 (1984).
18. 2 receptor agonist in patients with stable asthma. Thorax 58, 217-221 (2003).
19. Angus, R. M., Millar, E. A., Chalmers, G. W. & Thomson, N. C. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 151, 2003-2005 (1995).
20. Fluge, T. et al. Bronchodilation using combined urodilatin-albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial. Eur J. Med. Res. 4, 411-415 (1999).
21. Kidney, J. C. et al. Effect of an oral potassium channel activator BRL 38227 on airway function and responsiveness in asthmatic patients: comparison with oral salbutamol. Thorax 48 130-134 (1993).
22. Fox, A. J., Barnes, P. J., Venkatesan, P. & Belvisi, M. G. Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves. J. Clin. Invest. 99, 513-519 (1997).
23. 1-antihistamines in asthma. Clin. Allergy Immunol. 17, 221-248 (2002).
24. 4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 305, 1212-1221 (2003).
25. 4 Receptor Antagonist with Anti-inflammatory Properties. J. Pharmacol. Exp. Ther. (2004).
26. Drazen, J. M., Israel, E. & O'Byrne, P. M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340, 197-206 (1999).
27. Barnes, P. J. Anti-leukotrienes: here to stay? Curr. Opin. Pharmacol. 3, 257-263 (2003).
28. Back, M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 71, 611-622 (2002).
29. 4 antagonist LY293111 on allergen-induced responses in asthma. Thorax 51, 1178-1184 (1996).
30. Nasser, S. M. S. et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late responses. Thorax 49, 743-748 (1994).
31. 2 as a mediator of allergic asthma. Science 287, 2013-2017 (2000).
32. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255-261 (2001).
33. Benigni, A. & Remuzzi, G. Endothelin antagonists. Lancet 353, 133-138 (1999).
34. Kharitonov, S. A. & Barnes, P. J. Exhaled markers of pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 1693-1772 (2001).
35. Saleh, D., Ernst, P., Lim, S., Barnes, P. J. & Giaid, A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB J. 12, 929-937 (1998).
36. Guo, F. H. et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J. Immunol. 164 5970-5980 (2000).
37. Hansel, T. T. et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 17, 1298-1300 (2003).
38. Fozard, J. R. & McCarthy, C. Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs 3 69-77 (2002).
39. Yukawa, T. et al. Effect of theophylline and adenosine an eosinophil function. Am. Rev. Respir. Dis. 140, 327-333 (1989).
40. 2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. 438, 183-188 (2002).
41. 2Y receptors. J. Allergy Clin. Immunol. 107, 849-855 (2001).
42. Schulman, E. S. et al. ATP modulates anti-IgE-induced release of histamine from human lung mast cells. Am. J. Respir Cell. Mol. Biol. 20, 530-537 (1999).
43. He, S. & Walls, A. F. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. Eur. J. Pharmacol. 328, 89-97 (1997).
44. Knight, D. A. et al. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J. Allergy Clin. Immunol. 108, 797-803 (2001).
45. Clark, J. M. et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am. J. Respir. Crit. Care Med. 152, 2076-2083 (1995).
46. Krishna, M. T. et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J. Allergy Clin. Immunol. 107, 1039-1045 (2001).
47. Newhouse, B. J. Tryptase inhibitors - review of the recent patent literature. IDrugs. 5, 682-688 (2002).
48. Slusarchyk, W. A. et al. Synthesis of potent and highly selective inhibitors of human tryptase. Bioorg. Med. Chem. Lett. 12, 3235-3238 (2002).
49. Barnes, P. J. & Lim, S. Inhibitory cytokines in asthma. Mol. Med. Today 4, 452-458 (1998).
50. Barnes, P. J. Endogenous inhibitory mechanisms in asthma. Am. J. Respir. Crit. Care Med. 161, S176-S181 (2000).
51. Greenfeder S., Umland, S. P., Cuss, F. M., Chapman, R. W. & Egan, R. W. The role of interleukin-5 in allergic eosinophilic disease. Respir. Res. 2, 71-79 (2001).
52. Leckie, M. J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 356, 2144-2148 (2000).
53. Kips, J. C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003 ).
54. Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B. & Robinson, D. S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airways. Am. J. Respir. Crit. Care Med. (2003).
55. Morokata, T., Ida, K. & Yamada, T. Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int. Immunopharmacol. 2 1693-1702 (2002).
56. Steinke, J. W. & Borish, L. Interleukins-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2, 66-70 (2001).
57. Gavett, S. H. et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. 272, L253-61 (1997).
58. Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
59. Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
60. Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47-52 (2003).
61. Shanafelt, A. B. et al. An immune cell-selective interleukin 4 agonist. Proc. Natl Acad. Sci. USA 95, 9454-9458 (1998).
62. Jiang, H., Harris, M. B. & Rothman, P. IL-4/IL-13 signaling beyond JAK/STAT. J. Allergy Clin. Immunol. 105, 1063-1070 (2000).
63. Foster, P. S. STAT6: an intracellular target for the inhibition of allergic disease. Clin. Exp. Allergy 29, 12-16 (1999).
64. Wills-Karp, M. & Chiaramonte, M. Interleukin-13 in asthma. Curr. Opin. Pulm. Med 9, 21-27 (2003).
65. Walter, D. M. et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167, 4668-4675 (2001).
66. Kuperman, D. A. et al. Direct effects of interleukin- 13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nature Med. 8, 885-889 (2002).
67. Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261 (1998).
68. Levitt, R. C. et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J. Allergy Clin. Immunol. 103, S485-S491 (1999).
69. Longphre, M. et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J. Clin. Invest. 104, 1375-1382 (1999).
70. Shimbara, A. et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J. Allergy Clin. Immunol. 105, 108-115 (2000).
71. Cheng, G. et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med. 166, 409-416 (2002).
72. Zhou, Y., McLane, M. & Levitt, R. C. Interleukin-9 as a therapeutic target for asthma. Respir. Res. 2, 80-84 (2001 ).
73. Sousa, A. R., Lane, S. J., Nakhosteen, J. A., Lee, T. H. & Poston, R. N. Expression of interleukin-1β (IL-1β) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am. J. Respir. Crit. Care Med. 154, 1061-1066 (1996).
74. Arend, W. P., Malyak, M., Guthridge, C. J. & Gabay, C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16, 27-55 (1998).
75. Rosenwasser, L. J. Biologic activities of IL-1 and its role in human disease. J. Allergy Clin. Immunol. 102, 344-350 (1998).
76. Kips, J. C., Tavernier, J. H., Joos, G. F., Peleman, R. A. & Pauwels, R. A. The potential role of tumor necrosis factor α in asthma. Clin. Exp. Allergy 23, 247-250 (1993).
77. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-α therapies: the next generation. Nature Rev. Drug Discov. 2, 736-746 (2003).
78. Rabinowitz, M. H. et al. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem. 44, 4252-4267 (2001).
79. Barnes, P. J. IL-10: a key regulator of allergic disease. Clin. Exp. Allergy 31, 667-669 (2001).
80. Borish, L. et al. Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol. 97 1288-1296 (1996).
81. John, M. et al. Inhaled corticosteroids increase IL-10 but reduce MIP-1α, GM-CSF and IFN-γ release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 157, 256-262 (1998).
82. Zuany-Amorim, C. et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J. Clin. Invest. 95, 2644-2651 (1995).
83. Oh, J. W. et al. CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J. Allergy Clin. Immunol. 110, 460-468 (2002 ).
84. Jutel, M. et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003).
85. Fedorak, R. N. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 119, 1473-1482 (2000).
86. Seldon, P. M. & Giembycz, M. A. Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10. Br. J. Pharmacol. 134, 58-67 (2001).
87. Lack, G. et al. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice. J. Immunol. 157, 1432-1439 (1996).
88. Boguniewicz, M., Martin, R. J., Martin, D., Gibson, U. & Celniker, A. The effects of nebulized recombinant interferon-γ in asthmatic airways. J. Allergy Clin. Immunol. 95, 133-135 (1995).
89. Benjaponpitak, S. et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J. Allergy Clin. Immunol. 103, 468-475 (1999).
90. Durham, S. R. et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J. Allergy Clin. Immunol. 97, 1356-1365 (1996).
91. Simon, H. U., Seelbach, H., Ehmann, R. & Schmitz, M. Clinical and immunological effects of low-dose IFN-γ treatment in patients with corticosteroid-resistant asthma. Allergy 58, 1250-1255 (2003).
92. Dinarello, C. A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 11, 483-486 (2000).
93. Trinchieri, G., Pflanz, S. & Kastelein, R. A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19, 641-644 (2003).
94. Bryan, S. et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 356, 2149-2153 (2000).
95. Kim, T S. et al. An ovalbumin-IL- 12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol. 158, 4137-4144 (1997).
96. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
97. Proudfoot, A. E. Chemokine receptors: multifaceted therapeutic targets. Nature Rev. Immunol. 2, 106-115 (2002 ).
98. Gutierrez-Ramos, J. C., Lloyd, C. & Gonzalo, J. A. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol. Today 20, 500-504 (1999).
99. Ying, S. et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J. Immunol. 163, 6321-6329 (1999).
100. Gonzalo, J. A. et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J. Clin. Invest. 98, 2332-2345(1996).
101. Erin, E. M., Williams, T. J., Barnes, P. J. & Hansel, T. T. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr. Drug Targets. Inflamm. Allergy 1, 201-214 (2002).
102. Campbell, E. M. et al. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J. Immunol. 163, 2160-2167 (1999).
103. Lloyd, C. M. et al. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191, 265-274 (2000 ).
104. Chung, C. D. et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J. Immunol. 170, 581-587 (2003).
105. Lukacs, N. W., Berlin, A., Schols, D., Skerlj, R. T. & Bridger, G. J. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol. 160, 1353-1360 (2002).
106. Essayan, D. M. Cyclic nucleotide phosphodiesterases, J. Allergy Clin. Immunol. 108, 671-680 (2001).
107. Torphy, T. J. Phosphodiesterase isoenzymes. Am, J. Respir. Crit. Care Med. 157, 351-370 (1998).
108. Houslay, M. D. & Adams, D. R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18 (2003).
109. Giembycz, M. A. Cilomilast: a breath of relief? Trends Mol. Med. 7, 433-434 (2001).
110. Harbison, P. L. et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CD840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10, 1008-1014 (1997).
111. Reid, P. Roflumilast. Curr. Opin. Investig. Drugs 3 1165-1170 (2002).
112. Compton, C. H. et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358, 265-270 (2001).
113. Lamontagne, S. et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920, 84-96 (2001).
114. Jin, S. L. & Conti, M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl Acad. Sci. USA 99, 7628-7633 (2002).
115. Kuss, H., Hoefgen, N., Johanssen, S., Kronbach, T. & Rundfeldt, C. In vivo efficacy in airway disease models of N-(3, 5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J. Pharmacol. Exp. Ther. 307, 373-385 (2003).
116. Delhase, M., Li, N. & Karin, M. Kinase regulation in inflammatory response. Nature 406, 367-368 (2000).
117. Roshak, A. K., Callahan, J. F. & Blake, S. M. Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease. Curr. Opin. Pharmacol. 2, 316-321 (2002).
118. Nasuhara, Y., Adcock, I. M., Catley, M., Barnes, P. J. & Newton, R. Differential IKK activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κ B-dependent transcription. J. Biol. Chem. 274, 19965-19972 (1999).
119. Evans, D. J., Cullinan, P. & Geddes, D. M. Cyclosporin as an oral corticosteroid sparing agent in stable asthma (Cochrane Review). Cochrane. Database. Syst. Rev. 2, CD002993 (2001).
120. Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35, 7S-14S (2003).
121. Zhou, M. & Ouyang, W. The function role of GATA-3 in Th1 and Th2 differentiation. Immunol. Res. 28, 25-37 (2003).
122. Finotto, S. et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295, 336-338 (2002).
123. Kumar, S., Boehm, J. & Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Discov. 2, 717-726 (2003).
124. + T cells and Th2 effector cells. J. Immunol. 162, 7110-7119 (1999).
125. Kankaanranta, H., Giembycz, M. A., Barnes, P. J. & Lindsay, D. A. SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J. Pharmacol. Exp. Ther. 290, 621-628 (1999).
126. Irusen, E. et al. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. J. Allergy Clin. Immunol. 109, 649-657 (2002).
127. Huang, T. J., Adcock, I. M. & Chung, K. F. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br. J. Pharmacol. 134, 1029-1036 (2001).
128. Sousa, A. R., Lane, S. J., Soh, C. & Lee, T H. In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosylphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. J. Allergy Clin. Immunol. 104, 565-574 (1999).
129. Costello, P. S. et al. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 13, 2595-2605 (1996).
130. Yousefi, S., Hoessli, D. C., Blaser, K., Mills, G. B. & Simon, H. U. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J. Exp. Med. 183, 1407-1414 (1996).
131. Stenton, G. R. et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J. Immunol. 169, 1028-1036 (2002).
132. Amoui, M., Draber, P. & Draberova, L. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells. Eur. J. Immunol. 27, 1881-1886 (1997).
133. 4-induced eosinophil activation. Blood 95, 3541-3547 (2000).
134. Adachi, T., Stafford, S., Sur, S. & Alam, R. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J. Immunol. 163 939-946 (1999).
135. Schleimer, R. P. & Bochner, B. S. The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy. Clin. Exp. Allergy 28 Suppl. 3), 15-23 (1998).
136. Wegner, C. D. et al. Intracellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 247, 456-459 (1990).
137. Sun, J. et al. Contribution of intracellular adhesion molecule-1 in allergen-induced airway hyperresponsiveness and inflammation in sensitised Brown-Norway rats. Int Arch Allergy Immunol 104, 291-295 (1994).
138. Yamamoto, H. & Nagata, M. Regulatory mechanisms of eosinophil adhesion to and transmigration across endothelial cells by α4 and β2 integrins. Int. Arch. Allergy Immunol. 120 (Suppl. 1), 24-26 (1999).
139. Lin Kc et al. Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. J. Med. Chem. 42, 920-934 (1999).
140. Ghosh, S, et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
141. Abraham, W. M. et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am. J. Respir. Crit. Care Med. 159, 1205-1214 (1999).
142. Kim, M. K., Brandley, B. K., Anderson, M. B. & Bochner, B. S. Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am. J. Respir. Cell Mol. Biol. 19, 836-841 (1998).
143. Heinke, S., Szucs, G., Norris, A., Droogmans, G. & Nilius, B. Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br. J. Pharmacol. 115, 1393-1398 (1995).
144. Norris, A. A. & Alton, E. W. Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma. Clin. Exp. Allergy 26, 250-253 (1996).
145. Bianco, S. et al. Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur. Resp. J. 6, 130-134 (1993).
146. Yates, D. H. et al. Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am. J, Respir, Crit. Care Med. 152, 892-896 (1995).
147. Djukanovic, R. The role of co-stimulation in airway inflammation. Clin. Exp. Allergy 30 (Suppl. 1), 46-50 (2000).
148. Haczku, A. et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 159, 1638-1643 (1999).
149. Bugeon, L. & Dallman, M. J. Costimulation of T cells. Am. J. Respir. Crit. Care Med. 162, S164-S168 (2000).
150. Van Oosterhout, A. J. et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 17, 386-392 (1997).
151. Deurloo, D. T., van Esch, B. C., Hofstra, C. L., Nijkamp, F. P. & Van Oosterhout, A. J. CTLA4-IgG reverses asthma manifestations in a mild but not in a more 'severe' ongoing murine model. Am. J. Respir. Cell. Mol. Biol. 25, 751-760 (2001).
152. van Neerven, R. J. et al. Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin. Exp. Allergy 28, 808-816 (1998).
153. Gonzalo, J. A. et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nature Immunol. 2, 597-604 (2001).
154. Walker, S., Monteil, M., Phelan, K., Lasserson, T. J. & Walters, E. H. Anti-IgE for chronic asthma. Cochrane. Database. Syst. Rev. CD003559 (2003).
155. Rosenwasser, L. J., Busse, W. W., Lizambri, R. G., Olejnik, T. A. & Totoritis, M. C. Alergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 112, 563-570 (2003).
156. Hsu, C. H. et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Med. 2, 540-544 (1996).
157. Oldfield, W. L., Larche, M. & Kay, A. B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360, 47-53 (2002).
158. Herz, U. et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J. Allergy Clin. Immunol. 102, 867-874 (1998).
159. Choi, I. S. & Koh, Y. I. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann. Allergy Asthma Immunol. 88, 584-591 (2002).
160. Horner, A. A., Van Uden, J. H., Zubeldia, J. M., Broide, D. & Raz, E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev. 179, 102-118 (2001).
161. Sur, S. et al. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162, 6284-6293 (1999).
162. Kline, J. N., Kitagaki, K., Businga, T R. & Jain, V. V. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L170-L179 (2002).
163. Santeliz, J. V., Van Nest, G,, Traquina, P., Larsen, E. & Wills-Karp, M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109, 455-462 (2002).
164. Agrawal, S. & Kandimalla, E. R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8, 114-121 (2002).
165. Cookson, W. O. Asthma genetics. Chest 121, 7S-13S (2002).
166. Hall, I. P. Pharmacogenetics of asthma. Eur. Respir. J. 15, 449-451 (2000).
167. Powell, R. M., Hamilton, L. M., Holgate, S. T., Davies, D.E. & Holloway, J. W. ADAM33: a novel therapeutic target for asthma. Expert. Opin. Ther. Targets 7, 485-494 (2003).
168. Nyce, J. W. & Metzger, W. J. DNA antisense therapy for asthma in an animal model. Nature 385, 721-725 (1997).
169. Sandrasagra, A. et al. Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12, 177-181 (2002).
170. Morishita, R., Tomita, N., Kaneda, Y., & Ogihara, T. Molecular therapy to inhibit NF-κB activation by transcription factor decoy oligonucleotides. Curr. Opin. Pharmacol. 4, 139-146 (2004).
171. Wall, N. R. & Shi, Y. Small RNA: can RNA interference be exploited for therapy? Lancet 362, 1401-1403 (2003).
172. Zhang, X. et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279, 10677-10684 (2004).